Biosimilars: Substitution and Non-Medical Switching
In the past decade much has changed in the field of Biosimilars. This activity will address key elements of the topic as they exist in 2021. This is the second in a series on this topic.
At the conclusion of this activity, participants will be able to:
- List patient and physician concerns with third-party substitution of biosimilars
- Describe the concept of interchangeability- how it addresses physician and patient concerns; and what it means for pharmacy-level substitution of biologics.
- Describe the current status of US biosimilar substitution policy and its evolution at the state level
- Describe the US approach to automatic substitution with those of other countries including Australia, Canada, and those in Western and Eastern Europe
Philip J. Schneider, MS, FASHP
International Advisory Board Chair, Alliance for Safe Biologic Medicines
Philip Schneider has served as ASBM’s International Advisory Board chair since 2014. Schneider was Professor and Associate Dean for Academic and Professional Affairs for the University of Arizona, College of Pharmacy at the Phoenix Biomedical campus. In this position, he was responsible for the launch and growth of the College of Pharmacy program at the new Phoenix Biomedical Campus. He also held faculty appointments at the University of Arizona Colleges of Medicine and Public Health. He is a past president of the American Society of Health-System Pharmacists (ASHP) and past president of the American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.), having served for ten years as the first Editor-in-Chief of Nutrition in Clinical Practice, one of its two official publications. He is currently a Vice President of the International Pharmaceutical Federation.
No conflicts of interest exist
- 1.25 ACPEThe Arnold & Marie Schwartz College of Pharmacy and Health Sciences is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.